- Home
- NEGG vs ZURA Comparison
NEGG vs ZURA Comparison
Compare NEGG & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- ZURA
- Stock Information
- Founded
- NEGG 2001
- ZURA 2022
- Country
- NEGG United States
- ZURA United States
- Employees
- NEGG N/A
- ZURA N/A
- Industry
- NEGG Other Specialty Stores
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEGG Consumer Discretionary
- ZURA Health Care
- Exchange
- NEGG Nasdaq
- ZURA Nasdaq
- Market Cap
- NEGG 122.3M
- ZURA 69.9M
- IPO Year
- NEGG 2010
- ZURA N/A
- Fundamental
- Price
- NEGG $49.24
- ZURA $1.31
- Analyst Decision
- NEGG
- ZURA Buy
- Analyst Count
- NEGG 0
- ZURA 7
- Target Price
- NEGG N/A
- ZURA $14.33
- AVG Volume (30 Days)
- NEGG 646.8K
- ZURA 708.2K
- Earning Date
- NEGG 08-28-2025
- ZURA 08-08-2025
- Dividend Yield
- NEGG N/A
- ZURA N/A
- EPS Growth
- NEGG N/A
- ZURA N/A
- EPS
- NEGG N/A
- ZURA N/A
- Revenue
- NEGG $1,235,576,000.00
- ZURA N/A
- Revenue This Year
- NEGG N/A
- ZURA N/A
- Revenue Next Year
- NEGG N/A
- ZURA N/A
- P/E Ratio
- NEGG N/A
- ZURA N/A
- Revenue Growth
- NEGG N/A
- ZURA N/A
- 52 Week Low
- NEGG $3.32
- ZURA $0.97
- 52 Week High
- NEGG $56.00
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- NEGG 91.69
- ZURA 59.63
- Support Level
- NEGG $15.31
- ZURA $1.00
- Resistance Level
- NEGG $17.52
- ZURA $1.45
- Average True Range (ATR)
- NEGG 4.56
- ZURA 0.10
- MACD
- NEGG 2.70
- ZURA 0.03
- Stochastic Oscillator
- NEGG 85.35
- ZURA 68.89
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.